Cover Image
Market Research Report
Product code 
758980

Topical Absorbable Hemostats - Medical Devices Pipeline Assessment, 2019

Published: | GlobalData | 297 Pages | Delivery time: 1-2 business days

Price

Back to Top
Topical Absorbable Hemostats - Medical Devices Pipeline Assessment, 2019
Published: December 1, 2019
GlobalData
Content info: 297 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

GlobalData's Medical Devices sector report, "Topical Absorbable Hemostats - Medical Devices Pipeline Assessment, 2019" provides an overview of Topical Absorbable Hemostats currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Topical Absorbable Hemostats pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Topical Absorbable Hemostats under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Topical Absorbable Hemostats and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Topical Absorbable Hemostats under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date
Product Code: GDME0833EPD

Table of Contents

1. Table of Contents

  • 1.1 List of Tables 7
  • 1.2 List of Figures 11

2 Introduction 13

  • 2.1 Topical Absorbable Hemostats Overview 13

3 Products under Development 14

  • 3.1 Topical Absorbable Hemostats - Pipeline Products by Stage of Development 14
  • 3.2 Topical Absorbable Hemostats - Pipeline Products by Segment 15
  • 3.3 Topical Absorbable Hemostats - Pipeline Products by Territory 16
  • 3.4 Topical Absorbable Hemostats - Pipeline Products by Regulatory Path 17
  • 3.5 Topical Absorbable Hemostats - Pipeline Products by Estimated Approval Date 18
  • 3.6 Topical Absorbable Hemostats - Ongoing Clinical Trials 19

4 Topical Absorbable Hemostats - Pipeline Products under Development by Companies 20

  • 4.1 Topical Absorbable Hemostats Companies - Pipeline Products by Stage of Development 20
  • 4.2 Topical Absorbable Hemostats - Pipeline Products by Stage of Development 22

5 Topical Absorbable Hemostats Companies and Product Overview 24

  • 5.1 3-D Matrix Ltd Company Overview 24

List of Tables

  • Table 1: Topical Absorbable Hemostats - Pipeline Products by Stage of Development 15
  • Table 2: Topical Absorbable Hemostats - Pipeline Products by Segment 16
  • Table 3: Topical Absorbable Hemostats - Pipeline Products by Territory 17
  • Table 4: Topical Absorbable Hemostats - Pipeline Products by Regulatory Path 18
  • Table 5: Topical Absorbable Hemostats - Pipeline Products by Estimated Approval Date 19
  • Table 6: Topical Absorbable Hemostats - Ongoing Clinical Trials 20
  • Table 7: Topical Absorbable Hemostats Companies - Pipeline Products by Stage of Development 21
  • Table 8: Topical Absorbable Hemostats - Pipeline Products by Stage of Development 23
  • Table 9: 3-D Matrix Ltd Pipeline Products & Ongoing Clinical Trials Overview 25
  • Table 10: PuraStat Hemostat - Product Status 26
  • Table 11: PuraStat Hemostat - Product Description 26
  • Table 12: TDM-511 - Product Status 27
  • Table 13: TDM-511 - Product Description 27
  • Table 14: TDM-623 - Product Status 27
  • Table 15: TDM-623 - Product Description 27
  • Table 16: 3-D Matrix Ltd - Ongoing Clinical Trials Overview 28
  • Table 17: PuraStat Hemostat - A Multi-center, Single Arm Post-market Clinical Study to Confirm Safety and Performance of Purastat Absorbable Haemostatic Material for the Management of Bleeding after Open Liver Resection 29
  • Table 18: PuraStat Hemostat - A Multi-center, Single Arm Post-market Clinical Study to Confirm Safety and Performance of PuraStat Absorbable Haemostatic Material for the Management of Bleeding in Vascular Surgery 29
  • Table 19: PuraStat Hemostat - A Multicenter Prospective Observational Study to Evaluate the Utilization, Effectiveness and Safety of Purastat in the Management of Gastrointestinal Bleeding 30
  • Table 20: PuraStat Hemostat - The Hemostatic Potential of TDM-621 on Ascending Aortic Surgery 30
  • Table 21: Angiotech Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 31
  • Table 22: Hemaseel Thrombin Haemostatic Agent - Product Status 31
  • Table 23: Hemaseel Thrombin Haemostatic Agent - Product Description 31
  • Table 24: Anika Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 32
  • Table 25: Hemostatic Patch - Product Status 32
  • Table 26: Hemostatic Patch - Product Description 32
  • Table 27: APRUS Bio-Medical Innovations Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 33
  • Table 28: Deep Wound Hemostat - Product Status 33
  • Table 29: Deep Wound Hemostat - Product Description 33
  • Table 30: Arch Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 34
  • Table 31: AC5 - V - Product Status 34
  • Table 32: AC5 - V - Product Description 34
  • Table 33: AC5 Surgical Hemostatic Device - Product Status 35
  • Table 34: AC5 Surgical Hemostatic Device - Product Description 35
  • Table 35: AC5 Topical Gel - Product Status 35
  • Table 36: AC5 Topical Gel - Product Description 36
  • Table 37: Arch Therapeutics Inc - Ongoing Clinical Trials Overview 37
  • Table 38: AC5 Topical Gel - AC5 Topical Gel Skin Sensitization Study 38
  • Table 39: Baxter Healthcare Corp Pipeline Products & Ongoing Clinical Trials Overview 39
  • Table 40: Celstat Topical Hemostatic Dressing - Product Status 39
  • Table 41: Celstat Topical Hemostatic Dressing - Product Description 39
  • Table 42: Baxter International Inc Pipeline Products & Ongoing Clinical Trials Overview 40
  • Table 43: FloSeal Matrix Hemostatic Sealant - Product Status 40
  • Table 44: FloSeal Matrix Hemostatic Sealant - Product Description 41
  • Table 45: Hemopatch - Product Status 41
  • Table 46: Hemopatch - Product Description 41
  • Table 47: Hemopatch - Dural Defects - Product Status 42
  • Table 48: Hemopatch - Dural Defects - Product Description 42
  • Table 49: TISSEEL - Product Status 42
  • Table 50: TISSEEL - Product Description 43
  • Table 51: Baxter International Inc - Ongoing Clinical Trials Overview 44
  • Table 52: FloSeal Matrix Hemostatic Sealant - Blood-saving Effect of Combined Intravenous Tranexamic Acid with Topical Floseal Application, a Comparison with Intravenous Tranexamic Acid Only in Total Hip Arthroplasty 46
  • Table 53: FloSeal Matrix Hemostatic Sealant - Effectiveness of Gelatin Matrix with Human Derived Thrombin on Blood Loss, Surgical Time, Hospital Stay and Complications in Adolescents Undergoing Spine Surgery for Adolescent Idiopathic Scoliosis: A Randomized Clinical Trial 46
  • Table 54: FloSeal Matrix Hemostatic Sealant - Hemostatic Agent Use and Intraoperative Blood Loss in Lumbar Spine Surgery 46
  • Table 55: FloSeal Matrix Hemostatic Sealant - Impact of Electrocoagulation Versus a Gelantine-Thrombin Matrix Sealant (FloSeal) on Ovarian Reserve After Laparoscopic Stripping of Ovarian Endometriomas 47
  • Table 56: FloSeal Matrix Hemostatic Sealant - Intraoperative Bleeding Control with Thrombin-Gelatin-Matrix (Floseal) in Advanced Gynecologic Surgery. A Case-control Study with Special Focus on Hemostasis in Patients with Primary or Secondary Coagulapathies 47
  • Table 57: FloSeal Matrix Hemostatic Sealant - Management of Persistent Anterior Epistaxis Using Floseal Hemostatic Matrix vs. Traditional Nasal Packing: A Prospective Randomized Controlled Trial 47
  • Table 58: FloSeal Matrix Hemostatic Sealant - Prospective, Randomised, Controlled Investigation Comparing the Safety and Performance of 032-11 Surgical Haemostat with FLOSEAL Haemostatic Matrix in Cardiac Surgery and Thoracic Aortic Surgery 48
  • Table 59: FloSeal Matrix Hemostatic Sealant - The Role of Floseal in the Prevention of Lymphocele and Lymphatic Ascites After Lymph Node Dissection for Gynecologic Cancer: a Randomized Controlled Trial 48
  • Table 60: TISSEEL - Modified Muller's Muscle-conjunctival Resection Internal Ptosis Repair Using Fibrin Glue 49

List of Figures

  • Figure 1: Topical Absorbable Hemostats - Pipeline Products by Stage of Development 15
  • Figure 2: Topical Absorbable Hemostats - Pipeline Products by Segment 16
  • Figure 3: Topical Absorbable Hemostats - Pipeline Products by Territory 17
  • Figure 4: Topical Absorbable Hemostats - Pipeline Products by Regulatory Path 18
  • Figure 5: Topical Absorbable Hemostats - Pipeline Products by Estimated Approval Date 19
  • Figure 6: Topical Absorbable Hemostats - Ongoing Clinical Trials 20